Ny, the rotarod test, phenotyping, and cell culture experiments. M.E.D.-C. performed the morphological analyses. P.G.-G.

March 31, 2022

Ny, the rotarod test, phenotyping, and cell culture experiments. M.E.D.-C. performed the morphological analyses. P.G.-G. contributed towards the mitochondrial assays, proteomics experiments, along with the management from the mouse colony. R.Z.C. supervised the proteomics experiments and analyses. D.A.-C. contributed towards the discussions. L.C.L. conceived the concept for the project, supervised the experiments, and edited the manuscript. The outcomes shown within this short article constituted a section of A.H.-G.’s doctoral thesis in the University of Granada. All authors have read and agreed towards the published version in the manuscript. Funding: This work was supported by grants from Ministerio de Ciencia e Innovaci , Spain, plus the ERDF (grant quantity RTI2018-093503-B-100); from the Muscular Dystrophy Association (MDA602322); in the Junta de Andaluc (grant quantity P20_00134); from the University of Elinogrel site Granada (grant reference “UNETE,” UCE-PP2017-06); and by EPIC-XS, project number 823839, funded by the Horizon 2020 system of the European Union. P.G.-G. can be a “FPU fellow” in the Ministerio de Universidades, Spain. M.E.D.-C. is supported by the Muscular Dystrophy Association. E.B.-C. is supported by the Junta de Andaluc . A.H.-G. was partially supported by the “FPU program” and the research plan in the University of Granada. Data Availability Statement: The mass spectrometry proteomics information had been deposited for the ProteomeXchange (http://www.proteomexchange.org/ accessed on 1 April 2020). Consortium by way of the PRIDE companion repository together with the dataset identifier PXD018311 (1 April 2020).Biomedicines 2021, 9,25 ofAcknowledgments: We thank Seth Joel Drey for the English editing. We’re grateful to Ana Fernandez (Universidad de Granada) for her technical support in the facilities of bioanalysis. We thank members in the Heck Lab for their support in analyzing the proteomics samples. Conflicts of Interest: A.H.-G., M.E.D.-C., E.B.-C., P.G.-G. and L.C.L. are inventors on the patent application number P202031235.
biomedicinesArticleA Gadolinium DO3A Amide m-Phenyl Boronic Acid MRI Probe for Targeted Imaging of Sialated Solid TumorsChristu Rajan 1, , Jaya Seema 1, , Yu-Wen Chen 2 , Tsai-Chen Chen 1 , Ming-Huang Lin 1 , Chia-Huei Lin 1 and Dennis Wen-Han Hwang 1,two, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan; [email protected] (C.R.); [email protected] (J.S.); [email protected] (T.-C.C.); [email protected] (M.-H.L.); [email protected] (C.-H.L.) Biomedical Translation Research Center, Academia Sinica, Taipei 115, Taiwan; [email protected] Correspondence: [email protected] Those authors were contributed equally.Abstract: We developed a brand new probe, Gd-DO3A-Am-PBA, for imaging tumors. Our benefits showed active targeting of Gd-DO3A-Am-PBA to sialic acid (SA) moieties, with elevated cellular labeling in vitro and enhanced tumor accumulation and retention in vivo, in comparison to the commercial Gadovist. The effectiveness of our newly synthesized probe lies in its adequate retention phase, that is anticipated to provide a suitable time window for tumor diagnosis and a faster renal clearance, that will reduce toxicity dangers when translated to clinics. Therefore, this study can be extended to other tumor kinds that express SA on their surface. Targeting and MR imaging of any form of tumors also can be achieved by conjugating the newly synthesized contrast agent with precise antibodies. This study thus opens new.